Here we compare the published data from the STEP-1, SURMOUNT-1, and TRIUMPH-4 trials without marketing spin: -14,9% for semaglutide, -20,9% for the tirzepatide-28,7% for the retatrutideThe retatrutide vs tirzepatide vs semaglutide comparison also incorporates tolerance (dysesthesia 20,9% at the 12 mg dose level of retatrutide), pleiotropic effects 2024-2025 (apnea, heart failure, MASLD), and the updated regulatory status in France 2026
Preexisting Health Conditions Although BPC-157 is non-hormonal and generally well-tolerated, individuals with certain health conditions may be more sensitive to its effects
For midlife women navigating shifting hormones and stubborn weight, this combination can be a game-changer
Nutrition is especially important, since your cells are literally made from the foods you eat
While higher-income individuals may manage to afford GLP-1s OOP, lower-income individuals who are more likely to be affected by obesity will face significant access barriers